The Mayo Clinic Hepatobiliary SPORE has ongoing clinical trials.
Title: MC210103: Phase 1 trial of SCD I: A First in Human Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Activity of MTI-301 in Patients with Advanced Malignancy
Investigators: John A. Copland III, Ph.D.; Tushar C. Patel, M.B., Ch.B.; Kabir Mody, M.D.; Hani M. Babiker, M.D.; Steven R. Alberts, M.D., M.P.H.; Pooja Advani, M.B.B.S., M.D.; Winston Tan, M.D.
Contact: John A. Copland III, Ph.D.
Description: A Phase 1 clinical trial will test the safety of a novel first-in-class SCD1 inhibitor in cancer called MTI-301 (also known as SSI-4). We have developed a novel small molecule inhibitor blocking the activity of an enzyme, stearoyl CoA desaturase 1 (SCD1), which promotes fatty acid synthesis in cancer cells. These fatty acids promote tumor growth, metastasis and drug resistance. This pathway is broadly upregulated in aggressive cancers including hepatocellular carcinoma (HCC, liver cancer) and cholangiocarcinoma (CCA).
Anticipated start date: Fall/winter 2022
More about clinical trials
Learn more about clinical trials and studies, including types of studies and how Mayo Clinic puts the needs of patients first. Also, watch a video about discovery science and what happens in the research lab before clinical studies begin and how a discovery is transformed into a potential therapy ready to be tested in trials with human participants. Learn more.
Before clinical trials begin
This video demonstrates how discovery science works, what happens in the research lab before clinical studies begin, and how a discovery is transformed into a potential therapy ready to be tested in trials with human participants: